Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 3/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30300276 | 1.00 | AKR1C2 (0.50) | AKR1C2AKR1C1AKR1C3AKR1C4HSD17B10 | |
| SCHEMBL16098563 | 0.89 | AKR1C3 (0.56) | AKR1C2AKR1C1AKR1C3AKR1C4HSD17B10 | |
| SCHEMBL5854041 | 0.83 | AKR1C3 (0.61) | AKR1C2AKR1C1AKR1C3AKR1C4HSD17B10 | |
| SCHEMBL15994788 | 0.81 | DGAT1 (0.60) | AKR1C2AKR1C1AKR1C3AKR1C4HSD17B10 | |
| SCHEMBL30673278 | 0.81 | AKR1C2 (0.64) | AKR1C2AKR1C1AKR1C3AKR1C4HSD17B10 | |
| SCHEMBL25340705 | 0.81 | AKR1C3 (0.53) | AKR1C2AKR1C1AKR1C3AKR1C4HSD17B10 | |
| SCHEMBL1516725 | 0.81 | AKR1C2 (0.64) | AKR1C2AKR1C1AKR1C3AKR1C4HSD17B10 | |
| SCHEMBL20076066 | 0.81 | AKR1C3 (0.48) | AKR1C2AKR1C1AKR1C3AKR1C4HSD17B10 | |
| SCHEMBL16461500 | 0.81 | CES2 (0.42) | AKR1C2AKR1C1AKR1C3AKR1C4HSD17B10 | |
| SCHEMBL30431884 | 0.81 | AKR1C3 (0.48) | AKR1C2AKR1C1AKR1C3AKR1C4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737457-A1 | POLYSUBSTITUTED MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025002297-A1 | POLYSUBSTITUTED MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2025-01-02 | — | — | WO | disclosed |
| US-20240390350-A1 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2024-11-28 | — | — | US | disclosed |
| CN-118234718-A | Phenyl core compounds as MGLU5 negative allosteric modulators and methods of making and using the same | 范德比尔特大学 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023043823-A1 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20220289720-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | UNIVERSITY OF HAWAII | 2022-09-15 | — | — | US | disclosed |
| WO-2021016333-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | UNIVERSITY OF HAWAII (US) | 2021-01-28 | — | — | WO | disclosed |
| EP-3101013-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2606050-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | Cellzome Limited (GB) | 2013-06-26 | — | — | EP | disclosed |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2013-01-10 | — | — | US | disclosed |
| WO-2013006485-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2012022681-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | AKR1C2 1023/4885AKR1C1 997/4885AKR1C3 722/4885 |
| US-20240390350-A1 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | AKR1C2 4678/4885AKR1C1 4730/4885AKR1C3 4687/4885 |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | AKR1C2 3312/4885AKR1C1 2431/4885AKR1C3 2266/4885 |
| US-20220289720-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | STAT3, JAK2, STAT6 | AKR1C2 4188/4885AKR1C1 4457/4885AKR1C3 4351/4885 |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | AKR1C2 1023/4885AKR1C1 997/4885AKR1C3 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.